iShares' IYH or Invesco's PBE: Which Healthcare ETF Is the Better Long-Term Buy?

Invesco Biotechnology & Genome ETF (PBE) returned 46.7% over the past year versus 27.4% for iShares U.S. Healthcare ETF (IYH), but its five-year maximum drawdown was materially steeper at 34.7% versus 17.9%. IYH offers broader exposure across 100 healthcare holdings, $3.9B of AUM, and a lower 0.38% expense ratio, compared with PBE's 31-company biotech/genomics portfolio, $404.8M AUM, and 0.58% fee. The article favors IYH as a diversified, lower-cost long-term healthcare allocation, while positioning PBE as a higher-risk, concentrated biotech innovation play.

Analysis

This is not a fundamental catalyst for the underlying healthcare names; it is an allocation comparison with low expected near-term price-discovery value. The more relevant market signal is that a biotech sleeve has materially outperformed broad healthcare while retaining a substantially worse downside profile, a setup that often attracts late-cycle ETF flows after the highest-beta components have already rerated. PBE's modest asset base also makes its flows less informative and potentially more volatile than IYH's.

A broad-healthcare allocation is increasingly a concentrated large-cap pharma position rather than a neutral defensive basket. IYH's exposure to LLY, JNJ and ABBV means relative performance over the next 1-3 months will hinge disproportionately on GLP-1 pricing/reimbursement, IRA negotiation headlines, and pipeline readouts; it will not reliably hedge idiosyncratic pharma valuation risk. Conversely, PBE's rules-based rebalances can amplify momentum into smaller biotechnology constituents, creating transient demand but also sharper reversals if FDA outcomes or M&A expectations disappoint.

The contrarian view is that the apparent biotech leadership may be more fragile than the broad sector comparison implies: a year of strong returns without superior five-year compounding suggests multiple expansion and event-driven dispersion, not a durable portfolio-level earnings advantage. For a 6-18 month healthcare allocation, diversified exposure is preferable only if LLY's premium valuation is actively managed; otherwise an equal-weight biotech or selective large-cap basket may offer cleaner risk control than either cap-weighted vehicle.

Key Decisions for Investors

• No standalone trade on the article. Treat PBE/IYH relative flows as a watch item rather than a signal; require confirmation from biotechnology fund inflows, FDA-calendar catalysts, and upward 2027 EPS revisions before adding beta.
• For a 1-3 month defensive healthcare expression, prefer a modest long IYH paired with a partial short XLV or equal-dollar short exposure to LLY if its valuation premium expands further; this retains diversified healthcare exposure while reducing the dominant single-name multiple-risk. Exit if LLY guidance or reimbursement developments improve forward estimates materially.
• For event-driven risk capital, express biotech upside through a small long PBE / short IYH pair only after a pullback rather than chasing momentum. Target a 8-12% relative gain over 3-6 months; stop on a 5% relative loss or a broad deterioration in FDA approval/clinical-readout outcomes.
• Monitor ABBV, AMGN and REGN earnings revisions and M&A activity as the key falsifiers of a biotech mean-reversion view. Sustained positive revisions plus accelerating deal premiums would justify maintaining PBE exposure despite its higher drawdown risk.